№ lp_1_11929
File format: docx
Character count: 4463
File size: 25 KB
Gardasil-9 is a 9-valent HPV vaccine recommended for individuals aged 9 to 45 years to prevent various types of HPV-related cancers and genital warts, with a dosage schedule of three injections at specified intervals.
Year:
2023
Region / City:
N/A
Subject:
Vaccination
Document Type:
Medical Guidelines
Organization / Institution:
Merck
Author:
N/A
Target Audience:
Healthcare professionals
Effective Period:
N/A
Approval Date:
07/13/2015
Revision Dates:
07/13/2015, 11/15/2015, 06/2016, 04/2023, 08/2024
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Reference no:
HPV (GBMSM) PGD
Version no:
v5.0
Valid from:
1 September 2025
Review date:
1 April 2028
Expiry date:
1 September 2028
Author:
Suki Hunjunt, Sharif Ismail, David Green
Region / city:
England
Target audience:
Healthcare practitioners administering HPV vaccine to GBMSM
Type of document:
Patient Group Direction
Organisation:
UK Health Security Agency (UKHSA)
Date of approval:
17 July 2025
Date of modifications:
16 July 2025
Context:
A formal Patient Group Direction for the administration of HPV vaccine to GBMSM, detailing legal, clinical, and procedural requirements for healthcare practitioners in England.
Year:
2025
Region / city:
England
Topic:
Immunisation, HPV Vaccine
Document Type:
Patient Group Direction (PGD)
Organisation / institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare practitioners
Period of validity:
1 September 2025 - 1 September 2028
Approval Date:
1 September 2025
Review Date:
1 April 2028
Expiry Date:
1 September 2028
Year:
2023
Region / city:
Australia
Topic:
HPV vaccination recommendations
Document type:
Advisory report
Organization / institution:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Australian Technical Advisory Group on Immunisation (ATAGI)
Target audience:
Healthcare professionals, policy makers, the general public
Validity period:
Ongoing
Approval date:
30 January 2023
Amendment date:
30 January 2023
Year:
2015
Region / City:
Australia
Topic:
Immunization, HPV Vaccine
Document Type:
Health Policy
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
PBAC
Target Audience:
Health professionals, policymakers, researchers
Period of validity:
Ongoing from 2015
Date of approval:
June 29, 2015
Date of amendments:
January 2017
Year:
2026
Region / city:
USA, Austria, Norway, Brazil, Canada, Colombia, Denmark, UK, Australia
Subject:
Human papillomavirus vaccine, Cervical cancer prevention
Document Type:
Clinical trial report
Organization / institution:
Multiple research institutions and hospitals
Authors:
Warner K. Huh, Elmar A. Joura, Anna R. Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A. Ault, Deborah Bartholomew, Ramon M. Cestero, Edison N. Fedrizzi, Angelica L. Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T. Stapleton, Dorothy J. Wiley, Alex Ferenczy, Robert Kurman, Brigitte M. Ronnett, Mark H. Stoler, Jack Cuzick, Suzanne M. Garland, Susanne K. Kjaer, Oliver M. Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C. Roberts, Christine Shields, Alain Luxembourg
Target Audience:
Healthcare professionals, Researchers, Public health policymakers
Period of validity:
6 years
Approval date:
2026
Date of changes:
2026
Keywords:
human papillomavirus, vaccine, cervical cancer, persistent infection, cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia
Funding:
Merck & Co., Inc., Kenilworth, NJ, USA
Clinical trial registration:
NCT00543543 (https://clinicaltrials.gov/ct2/show/NCT00543543
Note:
)
Word count:
4963/4500
References:
30/30
Contextual description:
This clinical trial report presents the long-term efficacy, immunogenicity, and safety outcomes of a nine-valent HPV vaccine for preventing HPV-related cervical diseases in young women.
Year:
Not specified
Region / State:
Washington
Country:
United States
Topic:
Human papillomavirus (HPV) and vaccination
Document Type:
Informational letter
Issuing Authority:
Washington State Legislature
Related Institutions:
Washington State Department of Health; Centers for Disease Control & Prevention
Target Audience:
Parents or Guardians of public school students
Subject:
HPV infection, associated cancers, and vaccination recommendations
Legal Basis:
State requirement to provide HPV information to parents
Geographical Scope:
Public schools in Washington State
Referenced Program:
Childhood Vaccine Program
Year:
2026
Region:
Global
Topic:
Human papillomavirus (HPV) and vaccination
Document type:
Educational resource / Information guide
Target audience:
Parents, adolescents, health care providers, journalists, policymakers
Contents:
Questions and answers about HPV infection, vaccination, safety, effectiveness, and screening
Vaccines discussed:
HPV vaccines including quadrivalent and others
Health topics:
Cervical cancer, genital warts, HPV transmission, vaccination schedules
Production:
World Health Organization / relevant health authorities
Year:
2025
Region / city:
England
Topic:
Immunisation, HPV Vaccine
Document Type:
Patient Group Direction (PGD)
Organisation / institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare practitioners
Period of validity:
1 September 2025 - 1 September 2028
Approval Date:
1 September 2025
Review Date:
1 April 2028
Expiry Date:
1 September 2028
Year:
2023
Region / city:
Australia
Topic:
HPV vaccination recommendations
Document type:
Advisory report
Organization / institution:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Australian Technical Advisory Group on Immunisation (ATAGI)
Target audience:
Healthcare professionals, policy makers, the general public
Validity period:
Ongoing
Approval date:
30 January 2023
Amendment date:
30 January 2023
Note:
Year
Topic:
HPV Vaccination
Document type:
Instruction Manual
Organization / institution:
The DHS Program
Target audience:
Interviewers for DHS surveys
Context:
Instruction manual for interviewers on how to ask questions related to HPV vaccination during the DHS survey.
Year:
2020
Region / city:
United States
Topic:
HPV Vaccination, Cancer Prevention
Document Type:
Educational Resource
Organization:
National HPV Vaccination Roundtable
Author:
National HPV Vaccination Roundtable
Target Audience:
Nurses, Nurse Practitioners, Healthcare Professionals
Effective Period:
February 2020 - June 2020
Approval Date:
February 2020
Modification Date:
Not specified
Year:
2015
Region / city:
Global
Topic:
HPV Genotype and Cervical Intraepithelial Neoplasia
Document Type:
Table
Author:
Monsonego, Vaughan, Wheeler, Schiffman, Naucler, Kitchener, Smelov
Target Audience:
Researchers, Healthcare Professionals
Period of Effectiveness:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2024
Region / city:
Louga, Senegal
Topic:
HPV infection, Prevalence, Risk factors, Rural health
Document type:
Research study
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Public health professionals, Researchers, Healthcare providers
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Year:
Not specified
Region / State:
Washington
Country:
United States
Topic:
Human papillomavirus (HPV) and vaccination
Document Type:
Informational letter
Issuing Authority:
Washington State Legislature
Related Institutions:
Washington State Department of Health; Centers for Disease Control & Prevention
Target Audience:
Parents or Guardians of public school students
Subject:
HPV infection, associated cancers, and vaccination recommendations
Legal Basis:
State requirement to provide HPV information to parents
Geographical Scope:
Public schools in Washington State
Referenced Program:
Childhood Vaccine Program
Year:
2026
Region / city:
South Africa
Topic:
Human papilloma virus, oropharyngeal carcinomas, HPV vaccination, oral health
Document type:
Research Article
Institution:
University of Pretoria, Sefako Makgatho Health Sciences University
Authors:
CL Davidson, GE Khumalo, MGC Jordaan, SC Boy
Target audience:
Healthcare professionals, researchers, public health policymakers
Period of validity:
Not specified
Approval date:
Not specified
Revision date:
Not specified
Keywords:
HPV, oropharyngeal carcinomas, oral sex, men, cancer, HIV, vaccination
Study focus:
HPV-related cancers, HPV vaccination campaigns in South Africa, risk factors in oral HPV infections
Authors:
Susanna Kola-Palmer; Katie Dhingra
Academic degrees:
PhD
Year:
Not specified
Country:
United Kingdom
Research field:
Public health; oncology; psychology
Topic:
Awareness and knowledge of Human Papilloma Virus (HPV) and HPV testing
Document type:
Academic research article
Research design:
Cross-sectional internet-based survey
Sample size:
246 women
Participant characteristics:
Women aged 25 years and over (mean age 37.59)
Institutions:
University of Huddersfield; Leeds Beckett University
Corresponding author:
Susanna Kola-Palmer
Journal:
European Journal of Cancer Care
Funding:
No external funding
Conflicts of interest:
None declared
Key subjects:
HPV infection, cervical cancer prevention, HPV testing, HPV vaccination, cervical screening
Geographical focus:
United Kingdom
Data collection method:
Anonymous web-based questionnaire
Measurement instrument:
Psychometrically validated HPV knowledge questionnaire
Year:
2023
Region / city:
Delhi National Capital Region, India
Topic:
HPV vaccination, healthcare professionals, male reproductive health
Document Type:
Research Study
Organization:
National Leprosy Elimination Program, SRM Medical College Hospital & Research Centre, Amity University
Author:
Karuna Nidhi Kaur, Dhruva Nandi, Shanta Chandrasekaran, Alex Joseph, Shazina Saeed
Target audience:
Healthcare professionals, researchers, public health officials
Period of validity:
March 2022 - April 2023
Date of approval:
N/A
Date of revisions:
N/A
Year:
2026
Organism:
Escherichia coli ER2566
Target genes:
HPV L1 from types 6, 11, 16, 18, 31, 33, 45, 52, 58
Techniques:
PCR, SDS-PAGE, western blotting, chromosomal integration, plasmid-based expression
Gene loci:
lpxM, lpxP, pagP, lpxL, eptA, kdsD, gutQ
Type of document:
Supplementary material for a research study
Experiment scale:
Shake-flask and large-scale fermentation
Analysis:
Protein expression, plasmid maintenance, growth curves, transcript levels
Focus:
Comparative evaluation of single-copy versus multi-copy gene integration
Year:
2024
Region / City:
Lincoln, Lincolnshire, United Kingdom
Institution:
The Priory City of Lincoln Academy
Issuing Organization:
Lincolnshire Community Health Services
Department:
School Age Immunisation Service
Document Type:
School vaccination notification letter
Subject:
HPV vaccination for Year 8 students
Target Audience:
Parents and guardians of Year 8 students
Vaccination Program:
Human Papillomavirus (HPV) Immunisation Programme
Vaccination Period:
April–July
Consent Method:
Online consent or refusal form
Contact Telephone:
01522 572950
Signatory:
Anna Fisher
Position:
Professional Advisor, School Age Immunisations
Год:
2025
Тип документа:
Медицинское руководство
Орган / учреждение:
Клиническая практика / Поликлиника
Автор:
Медицинский персонал
Целевая аудитория:
Медсестры и клинические ассистенты
Тематика:
Скрининг, результаты лабораторных и радиологических тестов
Процедуры:
Обработка результатов, аннотирование, уведомление пациентов, план повторного вызова
Тесты:
HPV, цитология шейки матки, маммография, колоноскопия, PSA, наблюдение за раком почек и простаты, COVID-19, горловой мазок, спирометрия, ЭКГ
Период действия:
с 2025 года
Обновления:
указаны даты обработки результатов и уведомлений